Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 4/20 | 0.61 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.57 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.57 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ITGAV | P06756 | 2/20 | 0.51 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3848928 | 0.93 | ITGB1 (0.57) | ITGA4ITGB1ITGB7ITGA5ALDH1A1 | |
| SCHEMBL3848324 | 0.92 | ITGB1 (0.57) | ITGA4ITGB1ITGB7ITGA5ALDH1A1 | |
| SCHEMBL3855807 | 0.92 | ITGB1 (0.56) | ITGA4ITGB1ITGB7ITGA5ALDH1A1 | |
| SCHEMBL3852486 | 0.92 | ITGA4 (0.58) | ITGA4ITGB1ITGB7ITGA5FKBP1A | |
| SCHEMBL3857211 | 0.91 | ITGA4 (0.58) | ITGA4ITGB1ITGB7ITGA5ALDH1A1 | |
| SCHEMBL5609312 | 0.91 | ITGA4 (0.58) | ITGA4ITGB1ITGB7ITGA5ALDH1A1 | |
| SCHEMBL4415484 | 0.91 | ITGA4 (0.58) | ITGA4ITGB1ITGB7ITGA5ALDH1A1 | |
| SCHEMBL3850912 | 0.91 | ITGB1 (0.56) | ITGA4ITGB1ITGB7ITGA5ALDH1A1 | |
| SCHEMBL3848534 | 0.90 | ITGA4 (0.52) | ITGA4ITGB1ITGB7ITGA5ALDH1A1 | |
| SCHEMBL3853742 | 0.90 | ITGB1 (0.56) | ITGA4ITGB1ITGB7ITGA5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576101-B2 | Using sulfonamides such as N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-O-[1-methylpiperazin-4-ylcarbonyl]-L-tyrosine isopropyl ester optionally with immunoglobulins, steroids, antiinflammatory agents | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-7320960-B2 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | claimed |
| EP-1592386-A4 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARM INC (US) | 2007-06-13 | — | — | EP | claimed |
| US-20050272668-A1 | Anti-inflammatory compositions and methods | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2005-12-08 | — | — | US | claimed |
| EP-1592386-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | Elan Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| US-20050215565-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | BIOGEN MA INC. | 2005-09-29 | — | — | US | claimed |
| US-6939855-B2 | Anti-inflammatory compositions and method | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-06 | — | — | US | claimed |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | US | claimed |
| EP-1452532-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2004066931-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARMACEUTICALS INC. (US) | 2004-08-12 | — | — | WO | claimed |
| US-20040014677-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-22 | — | — | US | claimed |
| EP-0954519-B1 | ALPHA-9 INTEGRIN ANTAGONISTS AND ANTI-INFLAMMATORY COMPOSITIONS THEROF | ATHENA NEUROSCIENCES INC (US) | 2003-04-02 | — | — | EP | claimed |
| US-20030017993-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH | 2003-01-23 | — | — | US | claimed |
| US-20020193312-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-19 | — | — | US | claimed |
| US-6489300-B1 | INHIBITORS OF ADHESION IN THE TREATMENT OF INFLAMMATORY BRAIN DISEASES AND OTHER INFLAMMATORY CONDITIONS | ELAN PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | claimed |
| US-20020039745-A1 | ANTI-INFLAMMATORY COMPOSITIONS AND METHOD | WYETH | 2002-04-04 | — | — | US | claimed |
| EP-1000051-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| EP-0954519-A1 | ALPHA-9 INTEGRIN ANTAGONISTS AND ANTI-INFLAMMATORY COMPOSITIONS THEROF | ATHENA NEUROSCIENCES, INC. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1999006391-A1 | ALPHA-9 INTEGRIN ANTAGONISTS AND ANTI-INFLAMMATORY COMPOSITIONS THEROF | ATHENA NEUROSCIENCES, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| WO-1999006390-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030017993-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | ITGA4 8/4885ITGB1 64/4885ITGB7 296/4885 |
| US-20020193312-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | ITGA4 8/4885ITGB1 64/4885ITGB7 296/4885 |
| US-20040014677-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ITGA4 6/4885ITGB1 70/4885ITGB7 194/4885 |
| US-20050215565-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | MAG, PMP22, GAP43 | ITGA4 60/4885ITGB1 36/4885ITGB7 25/4885 |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ITGA4 3/4885ITGB1 8/4885ITGB7 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.